Keros Therapeutics (KROS) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Keros Therapeutics had a P/E ratio of 7.13, return on equity of 19.9% (up from -41.5%), debt-to-equity of 0.06 (up from 0.03) and a current ratio of 15.45 (down from 21.45). A current ratio of 15.45 means current assets exceed current liabilities.

Keros Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/E Ratio	7.13	-	-	-	-	-
P/S Ratio	2.54	180.63	7888.64	-	68.11	-
P/B Ratio	2.05	1.12	3.59	4.77	5.63	6.25
Price/Tangible Book	2.05	1.12	3.59	4.77	5.63	6.25
Price/FCF	5.85	-	-	-	-	-
Price/OCF	5.77	-	-	-	-	-
Enterprise Value Ratios
EV/Revenue	-	36.57	6076.87	-	57.16	-
Profitability & Returns
Return on Equity (ROE)	19.90%	-41.46%	-50.19%	-40.21%	-23.27%	-34.60%
Return on Assets (ROA)	9.25%	-26.73%	-31.39%	-25.53%	-13.43%	-20.80%
Return on Invested Capital (ROIC)	211.85%	-916.80%	-1251.82%	-887.57%	-1027.86%	-
Return on Capital Employed (ROCE)	22.20%	-35.80%	-49.20%	-39.60%	-23.20%	-17.80%
Leverage & Solvency Ratios
Debt/Equity	0.06	0.03	0.04	0.05	0.00	0.00
Debt/EBITDA	0.21	-	-	-	-	-
Debt/FCF	0.16	-	-	-	-	-
Liquidity Ratios
Current Ratio	15.45	21.45	14.25	17.27	21.23	37.27
Quick Ratio	15.10	20.56	13.63	16.91	20.96	37.04
Efficiency Ratios
Asset Turnover	0.51	0.01	0.00	-	0.08	-
Yield & Distribution Ratios
Earnings Yield	14.03%	-29.22%	-12.84%	-7.91%	-4.29%	-2.77%
FCF Yield	17.08%	-25.39%	-10.66%	-5.39%	-4.61%	-2.27%
Buyback Yield	-1.13%	-27.13%	-16.66%	-8.17%	-50.48%	-566.41%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Keros Therapeutics Financial Ratios

What is Keros Therapeutics's P/E ratio?

Keros Therapeutics's P/E ratio was 7.13 for fiscal 2025 (period ended Dec 31, 2025).

What is Keros Therapeutics's return on equity?

Keros Therapeutics's return on equity (ROE) was 19.9% for fiscal 2025 (period ended Dec 31, 2025). It was -41.5% a year earlier.

What is Keros Therapeutics's debt-to-equity ratio?

Keros Therapeutics's debt-to-equity ratio was 0.06 for fiscal 2025 (period ended Dec 31, 2025). It was 0.03 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition